Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix Shares Rise on News of Influenza Dx Service

NEW YORK, Dec. 6 (GenomeWeb News) - Shares in CombiMatrix were up $.07, or 4 percent, at $1.90 in mid-day trading after the company said it plans to offer a DNA-based microarray service to identify types of influenza.

 

The array will enable researchers to genetically identify influenza types, including the H5N1 bird flu. The company said the test can be run on both animal and human samples.

 

CombiMatrix Molecular Diagnostics, a wholly owned subsidiary of CombiMatrix formed in May, will offer the analysis for research purposes because the array is not an FDA approved product.

 

The Influenza microarray, part of CombiMatrix's CatalogArray product line, can detect and accurately type flu strains such as the H5N1 bird flu, as well as provide information on mutations and novel strains of flu not yet seen, the company said.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.